| Your link to the latest news on research, treatment, prevention and education from the state's
only National Cancer Institute - Designated Comprehensive Cancer Center |
|
| CINJ Researcher Presents Findings at National Meeting on Conservative Management as an Option for Elderly Men with Early-Stage Prostate Cancer |
Most elderly men diagnosed with early-stage prostate
cancer, who survive ten years, will be free from significant cancer-related
complications and are more likely to die of aliments other than prostate
cancer. That is according to researchers at CINJ, whose new study shows
that conservative management can be a viable option to older men diagnosed
with Stage I or Stage II prostate cancer in preserving their quality
of life in their later years. Grace Lu-Yao, PhD, MPH, cancer epidemiologist
at The Cancer Institute of New Jersey and associate professor of environmental
and occupational medicine at UMDNJ-Robert Wood Johnson Medical School
is the lead investigator on the study. She says it is critical for
patients to weigh the risk of treatment side effects and the risk of
cancer-related complications if the disease is left untreated. Most
men are diagnosed with prostate cancer after age 65 and may receive
modest benefit from aggressive cancer therapies. Since it may take
more than a decade for PSA-detected cancers to develop cancer-related
symptoms, it may not be necessary to rush into a treatment option,
which could potentially have adverse health affects. For many of them,
they will be able to live their lives with prostate cancer, but not
die from it. Dr. Lu-Yao stresses that the results of this study might
not be applicable to younger men. She notes elderly men who are diagnosed
with early-stage prostate cancer and choose conservative management
should have their PSA levels monitored on a regular basis and keep
a regular dialogue going with their doctor about options. Dr. Lu-Yao’s
study, “Prostate Disease Trajectory of Untreated Localized Prostate
Cancer in Elderly Men: A Population-Based Study,” was presented last
month at the annual Genitourinary Cancer Symposium, which is sponsored
by the American Society of Clinical Oncology. |
| |
| March is National Colorectal Cancer Awareness Month |
According to the American Cancer Society, more than 154,000 new cases of colorectal cancer were diagnosed in the United State last year with nearly 5,100 new cases in New Jersey. It is the third most common type of cancer in men and women and is the third leading cause of cancer death in the nation. While the exact cause of most colorectal cancers are not known, risk factors include poor diet, lack of exercise, and having polyps in the colon or rectum areas. Those over age 50 also are at increased risk. Beginning at age 50, it is recommended that men and women undergo a colonoscopy, fecal occult blood test or other screening that can detect colorectal cancer. Earlier testing is recommended for people with increased risk, such as those with a family history of the disease. Studies show that colorectal cancer may be prevented by maintaining a healthy weight, eating a diet rich in fruit and vegetables, keeping physically active and limiting use of alcoholic beverages. Physician-scientists at The Cancer Institute of New Jersey are currently investigating ways to improve the treatment and prevention of colorectal cancer. |
| |
| On-line Registration and Abstract Submission Now Available for the 2008 Annual Retreat on Cancer Research in New Jersey |
Each year, The Cancer Institute of New Jersey (CINJ) and the New
Jersey Commission on Cancer Research (NJCCR) host the Annual Retreat
on Cancer Research in New Jersey, a gathering of world-renowned scientists
from the cancer field. This year's retreat will be held on May
28, 2008 on the Piscataway Campus of the UMDNJ-Robert Wood Johnson
Medical School. Keynote speakers include Dr. David Allis, Joy and Jack
Fishman Professor and Head of the Laboratory of Chromatin Biology at
Rockefeller University, who will present “Beyond the Helix:
Writing and Reading the Histone Code” and Dr. Stephen Friend,
Executive Vice President of Oncology at Merck Research Laboratories,
who will present “Innovations in New Drug Development Through
Translational Research.” There will also be several poster
sessions highlighting the latest cancer research being conducted at
CINJ and other leading institutions throughout New Jersey. There is
no cost to attend the Annual Retreat on Cancer Research in New Jersey
but, registration is a must. On-line abstract submission for
the poster sessions and registration are now available at www.njcancerretreat.org. For
additional information please visit the web site or call 732-235-6785.
|
| |